Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Zelira Therapeutics Limited
  6. Summary
    ZLD   AU000000ZLD1

ZELIRA THERAPEUTICS LIMITED

(ZLD)
  Report
Delayed Australian Stock Exchange  -  05/23 11:19:30 pm EDT
1.400 AUD   +3.70%
05/16Zelira Therapeutics' Hope 1 Drug Shows Therapeutic Effects in Autism Spectrum Disorder Patients
MT
05/12Zelira Therapeutics Ltd Announces Resignation of Harry Karelis as Non-Executive Vice Chairman
CI
05/11TRANSCRIPT : Zelira Therapeutics Limited - Special Call
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Australian Stock Exchange
05/17/2022 05/18/2022 05/19/2022 05/20/2022 05/23/2022 Date
1.38(c) 1.275(c) 1.38(c) 1.63(c) 1.35(c) Last
21 309 12 618 4 993 25 315 16 440 Volume
+17.45% -7.61% +8.24% +18.12% -17.18% Change
More quotes
Estimated financial data (e)
Sales 2022 2,89 M 2,05 M 2,05 M
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Sales 2023 5,77 M 4,10 M 4,10 M
Net income 2023 - - -
Net Debt 2023 - - -
P/E ratio 2023 -
Yield 2023 -
Capitalization 15,6 M 11,1 M 11,1 M
Capi. / Sales 2022 5,41x
Capi. / Sales 2023 2,70x
Nbr of Employees -
Free-Float 87,4%
More Financials
Company
Zelira Therapeutics Limited is an Australia-based cannabinoid-based biopharmaceutical company. It is focused on developing and clinically validating branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its prescription (Rx) business, including insomnia, autism and chronic non-cancer pain. Its lead product, Zenivol, is a cannabinoid-based medicine for the treatment of chronic... 
Read more
More about the company
All news about ZELIRA THERAPEUTICS LIMITED
05/16Zelira Therapeutics' Hope 1 Drug Shows Therapeutic Effects in Autism Spectrum Disorder ..
MT
05/12Zelira Therapeutics Ltd Announces Resignation of Harry Karelis as Non-Executive Vice Ch..
CI
05/11TRANSCRIPT : Zelira Therapeutics Limited - Special Call
CI
05/08Zelira Therapeutics Launches New Relief Cream Product
MT
05/08Zelira Therapeutics Limited Successfully Launches ITURA with CVSCM
CI
04/28Zelira Therapeutics Logs $340,000 Cash Receipts in Fiscal Q3; Shares Fall 3%
MT
04/21ZELIRA THERAPEUTICS : Update - Consolidation/Split - ZLD
PU
04/18ZELIRA THERAPEUTICS : and Health House execute Scheme Implementation Deed
PU
04/14ZELIRA THERAPEUTICS LIMITED : REVERSE SPLIT: 1 of 175
FA
04/12ZELIRA THERAPEUTICS : Update - Consolidation/Split - ZLD
PU
04/11TRANSCRIPT : Zelira Therapeutics Limited - Shareholder/Analyst Call
CI
04/05Zelira Therapeutics Limited Announces Update on EDCDM Technology Licence Agreement
CI
03/13ZELIRA THERAPEUTICS : Consolidation/Split - ZLD
PU
02/28ZELIRA THERAPEUTICS : Appendix 4D & FY22 Interim Financial Report
PU
02/28ZELIRA THERAPEUTICS : Application for quotation of securities - ZLD
PU
More news
News in other languages on ZELIRA THERAPEUTICS LIMITED
05/12Zelira Therapeutics Ltd annonce la démission de Harry Karelis en tant que vice-présiden..
05/08Zelira Therapeutics Limited lance avec succès ITURA avec CVSCM
04/28Zelira Therapeutics enregistre des rentrées de fonds de 340 000 $ au troisième trimestr..
04/05Zelira Therapeutics Limited annonce une mise à jour sur l'accord de licence de la techn..
02/23Zelira Therapeutics Limited annonce ses résultats pour le semestre clos le 31 décembre ..
More news
Chart ZELIRA THERAPEUTICS LIMITED
Duration : Period :
Zelira Therapeutics Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZELIRA THERAPEUTICS LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 1,35 AUD
Average target price 11,70 AUD
Spread / Average Target 767%
Managers and Directors
Oludare Odumosu Chief Executive Officer, Director & MD
Osagie O. Imasogie Chairman
Timothy Ryan Slate Secretary & Non-Executive Director
Lisa Gray Director
Jason William Peterson Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
ZELIRA THERAPEUTICS LIMITED-71.77%11
GILEAD SCIENCES, INC.-12.33%80 075
REGENERON PHARMACEUTICALS, INC.7.98%71 235
VERTEX PHARMACEUTICALS22.20%66 136
WUXI APPTEC CO., LTD.-17.77%42 735
BIONTECH SE-36.77%39 612